Literature DB >> 26076804

Pericytes in sarcomas of bone.

Le Chang1, Vi Nguyen, Alan Nguyen, Michelle A Scott, Aaron W James.   

Abstract

Pericytes are mesenchymal cells that closely enwrap small blood vessels, lying in intimate association with the endothelium. Pericytes have recently gained attention as an important mediator of vascular biology and angiogenesis in cancer. Although better studied in carcinoma, pericytes have known interaction with sarcomas of bone, including Ewing's sarcoma, osteosarcoma, and chondrosarcoma. Best studied is Ewing's sarcoma (ES), which displays a prominent perivascular growth pattern. Signaling pathways of known importance in intratumoral pericytes in ES include Notch, PDGF/PDGFR-β, and VEGF signaling. In summary, pericytes serve important functions in the tumor microenvironment. Improved understanding of pericyte biology may hold significant implications for the development of new therapies in sarcoma.

Entities:  

Mesh:

Year:  2015        PMID: 26076804     DOI: 10.1007/s12032-015-0651-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  86 in total

Review 1.  Role of pericytes in vascular morphogenesis.

Authors:  Christer Betsholtz; Per Lindblom; Holger Gerhardt
Journal:  EXS       Date:  2005

2.  Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness.

Authors:  P Zhang; Y Yang; R Nolo; P A Zweidler-McKay; D P M Hughes
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

3.  EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.

Authors:  Zhichao Zhou; Ling Yu; Eugenie S Kleinerman
Journal:  Cancer       Date:  2014-01-10       Impact factor: 6.860

Review 4.  How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize.

Authors:  Dennis P M Hughes
Journal:  Cancer Treat Res       Date:  2009

5.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.

Authors:  P Lindahl; B R Johansson; P Levéen; C Betsholtz
Journal:  Science       Date:  1997-07-11       Impact factor: 47.728

6.  Prostaglandin I2 analog suppresses lung metastasis by recruiting pericytes in tumor angiogenesis.

Authors:  Yoshinori Minami; Takaaki Sasaki; Hiroki Bochimoto; Jun-Ichi Kawabe; Satoshi Endo; Yoshiki Hira; Tsuyoshi Watanabe; Shunsuke Okumura; Naoyuki Hasebe; Yoshinobu Ohsaki
Journal:  Int J Oncol       Date:  2014-11-28       Impact factor: 5.650

Review 7.  Current treatment of osteosarcoma.

Authors:  W S Ferguson; A M Goorin
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

8.  Effect of platelet-derived growth factor-B on renal cell carcinoma growth and progression.

Authors:  Wenling Wang; Lifeng Qi; Minhan Tan; Zhenting Zhang; Ju Du; Xiaona Wei; Xin Yao
Journal:  Urol Oncol       Date:  2015-03-09       Impact factor: 3.498

Review 9.  Interactions between VEGFR and Notch signaling pathways in endothelial and neural cells.

Authors:  Jean-Leon Thomas; Kasey Baker; Jinah Han; Charles Calvo; Harri Nurmi; Anne C Eichmann; Kari Alitalo
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

10.  Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.

Authors:  Zhichao Zhou; Marcela F Bolontrade; Krishna Reddy; Xiaoping Duan; Hui Guan; Ling Yu; Daniel J Hicklin; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

View more
  2 in total

1.  Neuronal Repressor REST Controls Ewing Sarcoma Growth and Metastasis by Affecting Vascular Pericyte Coverage and Vessel Perfusion.

Authors:  Zhichao Zhou; Yuanzheng Yang; Fei Wang; Eugenie S Kleinerman
Journal:  Cancers (Basel)       Date:  2020-05-29       Impact factor: 6.639

Review 2.  Carcinoma and Sarcoma Microenvironment at a Glance: Where We Are.

Authors:  Mattia Saggioro; Edoardo D'Angelo; Gianni Bisogno; Marco Agostini; Michela Pozzobon
Journal:  Front Oncol       Date:  2020-03-03       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.